“The present circumstance has exposed some structural weaknesses within the EU’s medicines offer chain as well as a higher dependence on non-EU countries for active pharmaceutical ingredients,” Kyriakides mentioned. She advisable that offer chain challenges be addressed within an EU pharmaceutical system envisioned to get launched by the end